Abstract

Previous studies showed a strong association between sarcoidosis and heart failure (HF) but did not consider risk stratification or risk factors to identify useful aetiological insights. We estimated overall and stratified HRs and identified risk factors for HF in sarcoidosis.

Methods

Sarcoidosis cases were identified from the Swedish National Patient Register (NPR; ≥2 International Classification of Diseases-coded visits, 2003–2013) and matched to general population comparators. They were followed for HF in the NPR. Treated were cases who were dispensed ≥1 immunosuppressant ±3 months from the first sarcoidosis visit (2006–2013). Using Cox models, we estimated HRs adjusted for demographics and comorbidity and identified independent risk factors of HF together with their attributable fractions (AFs).

Results

During follow-up, 204 of 8574 sarcoidosis cases and 721 of 84192 comparators were diagnosed with HF (rate 2.2 vs 0.7/1000 person-years, respectively). The HR associated with sarcoidosis was 2.43 (95% CI 2.06 to 2.86) and did not vary by age, sex or treatment status. It was higher during the first 2 years after diagnosis (HR 3.7 vs 1.9) and in individuals without a history of ischaemic heart disease (IHD; HR 2.7 vs 1.7). Diabetes, atrial fibrillation and other arrhythmias were the strongest independent clinical predictors of HF (HR 2.5 each, 2-year AF 20%, 16% and 12%, respectively).

Conclusions

Although low, the HF rate was more than twofold increased in sarcoidosis compared with the general population, particularly right after diagnosis. IHD history cannot solely explain these risks, whereas ventricular arrhythmias indicating cardiac sarcoidosis appear to be a strong predictor of HF in sarcoidosis.
Heart failure and cardiomyopathies

participant’s unique identification number which is allocated by authorities at birth or immigration.

Patient and public involvement

Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research.

Follow-up for HF

The study population was followed for HF, which was defined as an inpatient or outpatient visit in the NPR listing an ICD code for HF or cardiomyopathy as the primary discharge diagnosis (see online supplemental table S1 for codes). This definition for HF yielded positive predictive values of >80% in validation studies. Follow-up started at index date and ended at the earliest of hospital admission or outpatient visit for HF, emigration (Total Population Register), death (Cause of Death Register) or 31 December 2013. Individuals with a history of HF at the start of follow-up were excluded from all analyses.

Other variables and predictors of HF

Demographic variables were evaluated at the start of follow-up using data obtained from the Total Population Register and the Longitudinal Integrated Database for Health Insurance and Labor Market Studies. They included age, sex, region of residence (grouped into six healthcare regions), country of birth (Nordic, non-Nordic or missing), attained education (≤9, 10–12, ≥13 years or missing) and civil status (married or in registered partnership, or other).

Using nationwide data on filled prescriptions that first became available in the Prescribed Drug Register (PDR) in July 2005, we classified sarcoidosis cases who entered the cohort in 2006 or later as treated around diagnosis if they were dispensed ≥1 systemic corticosteroid, methotrexate or azathioprine ≥3 months from the first sarcoidosis visit. We aimed to capture sarcoidosis cases with debilitating or progressing disease at diagnosis for whom treatment with immunosuppressants is recommended (see codes in online supplemental table S1). To account for differences in general health status, we counted NPR visits within 2 years before the first sarcoidosis visit or the corresponding date for comparators (0, 1–3, ≥4 visits).

In addition, we evaluated several clinical confounders and/or potential predictors of HF using data on healthcare visits or medical procedures from the NPR and/or medication dispensations in the PDR, as appropriate (see online supplemental table S1). Comorbidities included hypertension, diabetes mellitus, dyslipidaemia, IHD including acute myocardial infarction (AMI), heart valve disease, atrial fibrillation, other arrhythmias (a composite variable made up of ventricular arrhythmias, conduction anomalies, cardiac arrest, implantation of a cardioverter-defibrillator, receipt of cardiac resynchronisation therapy or ≥2 dispensations of a class I/III antiarrhythmic medication), pulmonary hypertension, chronic obstructive pulmonary disease, chronic kidney disease, alcohol-related disorders and autoimmune disease. When used as confounders, comorbidities were evaluated 3 months before the first sarcoidosis visit or the corresponding date in comparators to avoid surveillance bias favouring the sarcoidosis group. Last, we defined use of medications that could have altered the risk of HF at baseline as ≥1 dispensation in the PDR between 3 and 9 months before the first sarcoidosis visit or the corresponding date for comparators.

Statistical analysis

We estimated incidence rates and rate differences comparing sarcoidosis with the general population and their corresponding 95% CIs using Poisson regression models adjusted for age, sex and region of residence. We used Cox proportional hazards models with attained age as the time scale to estimate HRs of HF comparing sarcoidosis with the general population. Models were sequentially adjusted for: (1) age, sex and region of residence; (2) country of birth, education, civil status and calendar period; (3) hypertension, diabetes mellitus, dyslipidaemia, heart valve disease, atrial fibrillation, chronic obstructive pulmonary disease, chronic kidney disease, alcohol-related disorders, autoimmune disease, and healthcare visits within 2 years before the first sarcoidosis visit or corresponding period for comparators. Unless otherwise stated, the missing-indicator method was used to account for missingness in country of birth and education.

We further investigated differences in HRs comparing sarcoidosis with the general population among groups defined by age at start of follow-up (18–44, 45–64, or 65–85 years), sex, sarcoidosis treatment status around diagnosis (treated vs untreated), time since start of follow-up (≤2 vs >2 years when sarcoid inflammation is expected to subside in about 50% of cases) and by history of IHD/AAMI, both causes of ischaemic HF. A two-tailed p value of <0.05 from a likelihood ratio test was considered indicative of significant differences among groups.

Restricting to the sarcoidosis cohort, we used a Cox model with years since sarcoidosis diagnosis as the time scale adjusted for age at sarcoidosis diagnosis, sex, region of residence, country of birth and education to examine whether predefined predictors evaluated at sarcoidosis diagnosis (second NPR visit) were independently associated with HF. To rank the clinical predictors according to their potential contribution of HF cases, we estimated the attributable fraction at 2 and 10 years after sarcoidosis diagnosis.

We conducted several sensitivity analyses which are detailed in the online supplemental methods section.

We used SAS V9.4 (SAS Institute) and R V.4.0.2 (R Foundation for Statistical Computing, Vienna, Austria) for data management and analyses.

RESULTS

We followed 8574 individuals with sarcoidosis and 84 192 matched general population comparators for HF. Mean age at start of follow-up was 49 years (SD 14 years) and 45% of participants were women (table 1). Hypertension, diabetes, dyslipidaemia, atrial fibrillation, chronic obstructive pulmonary, chronic kidney and autoimmunity disease were more prevalent in sarcoidosis. Of individuals with sarcoidosis who entered the cohort in 2006 and onwards with available data in the PDR, 41% were dispensed an immunosuppressant treatment around the time of diagnosis. Sarcoidosis cases were more likely to have been dispensed medications used to treat comorbidities (eg, diuretics or β-blockers) than comparators (online supplemental table S2).

Association between sarcoidosis and HF

During a median follow-up of 4.8 years (IQR 2.3–7.6), 204 individuals with sarcoidosis and 721 general population comparators were diagnosed with HF. The incidence rate of HF was higher in sarcoidosis (2.2/1000 person-years [95% CI 1.9 to 2.6]) than in comparators (0.7/1000 person-years [95% CI 0.7 to 0.8]; table 2). After adjusting for demographics and comorbidity, sarcoidosis was associated with a 2.4-fold higher risk of HF (HR 2.43 [95% CI 2.06 to 2.86]; table 3). The proportional hazards
assumption was visualised using Schoenfeld residuals plots and was found to hold in all analyses. The HR did not vary by age (p=0.77), sex (p=0.38) or treatment status around sarcoidosis diagnosis (p=0.29). It was, however, higher during the first 2 years compared with the rest of follow-up (fully adjusted HR 3.74 (95% CI 2.93 to 4.77) vs 1.86 (95% CI 1.50 to 2.31); p<0.001) and in individuals without compared with those with a history of IHD/AMI (HR 2.74 (95% CI 2.28 to 3.29) vs 1.70 (95% CI 1.19 to 2.44); p=0.02; table 3).

Predictors of HF in sarcoidosis

As shown in table 4, individuals with sarcoidosis who developed HF were more likely to be older, have lower education and more comorbidity (eg, diabetes, IHD, etc) than those who did not develop HF. Arrhythmias were also more common at sarcoidosis diagnosis in those who were diagnosed with HF during follow-up. In a mutually adjusted Cox model including demographic and other clinical predictors, diabetes mellitus, atrial fibrillation, and other arrhythmias were each independently associated with a 2.5-fold increased risk of HF (table 4) and were each estimated to account for 20%, 16%, and 12% of HF cases at 2 years after sarcoidosis diagnosis, respectively (attributable fraction; figure 1). Although history of IHD was one of the most prevalent comorbidities in those who developed HF, it was associated with a 40% increased risk of HF diagnosis during follow-up (mutually adjusted HR 1.4 (95% CI 1.0 to 2.1); attributable fraction at 2 years 7%).

In separate analyses restricting to those diagnosed with sarcoidosis 2006–2013, sarcoidosis treatment status around diagnosis (treated/untreated) and cumulative defined daily doses (DDDs) of systemic corticosteroids within 6 months before sarcoidosis diagnosis did not independently predict HF (online supplemental tables S4 and S5). However, dispensation of >300 DDDs (high tertile; one DDD prednisolone=10 mg) of systemic corticosteroids within 6 months after sarcoidosis diagnosis was associated with a twofold increased risk of HF after 6 months compared with ≤150 DDDs (low tertile; online supplemental table S5). Time-varying analyses resulted in a somewhat higher HRs than those from the main analysis for other arrhythmias and IHD (3.1 (95% CI 2.2 to 4.3) and 1.9 (95% CI 1.4 to 2.6), respectively), whereas associations for other predictors did not change markedly (online supplemental table S6).

DISCUSSION

In this large study, sarcoidosis was associated with a 2.4-fold increased hazard of HF compared with the general population. The HR of HF was highest during the first 2 years after sarcoidosis diagnosis (HR 3.7) but did not vary by age, sex or sarcoidosis treatment status around diagnosis. A higher HR of HF associated with sarcoidosis was observed in individuals without a history of IHD around diagnosis in those who were diagnosed with HF during follow-up. Arrhythmias were also more common at sarcoidosis diagnosis in those without a history of IHD compared with those with a history of IHD/AMI, but HF was also seen in younger patients with sarcoidosis and in those without a history of IHD. These findings together with an increased HR of HF.

In sensitivity analyses, we found a similar HR to the main analysis when we disregarded HF diagnoses during the first 6 months to account for potential surveillance bias in sarcoidosis (overall HR 2.30 (95% CI 1.94 to 2.74); HR within 2 years from sarcoidosis diagnosis (3.50 (95% CI 2.64 to 4.63)) and a slightly attenuated HR (1.87 (95% CI 1.62 to 2.15)) when we included secondary diagnoses in the HF definition (online supplemental table S3).
Heart failure and cardiomyopathies during the first 2 years since sarcoidosis diagnosis, a period of active inflammation in most individuals, suggested that HF and sarcoidosis may be linked by common pathogenetic mechanisms. Interestingly and similar to a smaller investigation, HRs of HF were not significantly different between sarcoidosis cases who did and did not receive immunosuppressant treatment around diagnosis. Contrary to what we previously observed for mortality and infection risks, treatment status around diagnosis might not be useful for stratifying patients with sarcoidosis in terms of future HF risk. We should acknowledge,

### Table 2

| Incidence rates and rate differences of heart failure (per 1000 person-years) comparing sarcoidosis with the general population, overall and by age at start of follow-up, sex, sarcoidosis treatment status around sarcoidosis diagnosis, time since sarcoidosis diagnosis, and history of ischaemic heart disease or acute myocardial infarction |
|-----------------|-----------------|-----------------|
| **Sarcoidosis** | **Incidence rate** (95% CI) | **General population** | **Incidence rate** (95% CI) |
| **Events/ N at risk** | **Events/ N at risk** | **Rate difference** (95% CI) |
| Overall | 204/8574 | 2.2 (1.9 to 2.6) | 721/84192 | 0.7 (0.7 to 0.8) | 1.5 (1.1 to 1.8) |
| Age at start of follow-up, years | | | |
| 18–44 | 18/3699 | 0.8 (0.5 to 1.3) | 53/36549 | 0.2 (0.2 to 0.3) | 0.6 (0.2 to 1.0) |
| 45–64 | 68/3394 | 3.3 (2.6 to 4.3) | 225/33578 | 1.1 (0.9 to 1.3) | 2.2 (1.4 to 3.1) |
| 65–85 | 118/1481 | 19.0 (15.8 to 22.9) | 443/14065 | 6.6 (5.9 to 7.3) | 12.5 (8.9 to 16.0) |
| Sex | | | |
| Female | 90/3824 | 1.8 (1.4 to 2.4) | 329/37606 | 0.6 (0.5 to 0.8) | 1.2 (0.8 to 1.6) |
| Male | 114/4750 | 2.4 (2.0 to 3.0) | 392/46586 | 0.8 (0.7 to 0.9) | 1.6 (1.2 to 2.1) |
| Sarcoidosis treatment around diagnosis† | | | |
| Treated | 62/2696 | 3.0 (2.2 to 4.1) | 161/26479 | 0.7 (0.6 to 0.9) | 2.3 (1.4 to 3.1) |
| Untreated | 79/3889 | 2.1 (1.6 to 2.8) | 234/38120 | 0.6 (0.5 to 0.8) | 1.5 (1.0 to 2.0) |
| Time since sarcoidosis diagnosis, years | | | |
| ≤2 | 98/8574 | 1.2 (0.9 to 1.5) | 223/84192 | 0.5 (0.4 to 0.6) | 0.7 (0.4 to 0.9) |
| >2 | 106/6585 | 1.0 (0.8 to 1.3) | 498/65949 | 0.2 (0.2 to 0.3) | 0.8 (0.5 to 1.0) |
| History of ischaemic heart disease or acute myocardial infarction | | | |
| Yes | 37/339 | 26.9 (19.4 to 37.4) | 186/2735 | 13.6 (11.5 to 16.1) | 13.3 (4.4 to 22.2) |
| No | 167/8235 | 2.1 (1.8 to 2.5) | 535/81457 | 0.6 (0.6 to 0.7) | 1.5 (1.1 to 1.8) |

*Rates and rate differences per 1000 person-years were estimated using Poisson regression models adjusted for age, sex (if applicable) and region of residence.†Evaluated in individuals with start of follow-up from 2006 and onwards for whom medication dispensation data were available in the Prescribed Drug Register.

### Table 3

| HR* (95% CI) |
|-----------------|-----------------|-----------------|
| **HRs of heart failure comparing sarcoidosis with the general population, overall and by age at start of follow-up, sex, sarcoidosis treatment status around sarcoidosis diagnosis, time since sarcoidosis diagnosis, and history of ischaemic heart disease or acute myocardial infarction** |
| **Multivariable model 1** | **Multivariable model 2** | **Multivariable model 3** |
| Overall | 3.03 (2.59 to 3.53) | 3.05 (2.61 to 3.57) | 2.43 (2.06 to 2.86) |
| Age at start of follow-up, years | | | |
| 18–44 | 3.34 (1.96 to 5.70) | 3.29 (1.93 to 5.61) | 2.79 (1.63 to 4.78) |
| 45–64 | 3.09 (2.35 to 4.05) | 3.14 (2.39 to 4.12) | 2.53 (1.92 to 3.34) |
| 65–85 | 2.95 (2.41 to 3.62) | 2.98 (2.43 to 3.65) | 2.32 (1.88 to 2.87) |
| Sex | | | |
| Female | 2.92 (2.31 to 3.68) | 2.95 (2.33 to 3.72) | 2.25 (1.77 to 2.86) |
| Male | 3.12 (2.53 to 3.84) | 3.14 (2.55 to 3.87) | 2.59 (2.08 to 3.21) |
| Sarcoidosis treatment around diagnosis† | | | |
| Treated | 4.23 (3.15 to 5.66) | 4.24 (3.17 to 5.69) | 3.35 (2.48 to 4.53) |
| Untreated | 3.43 (2.66 to 4.43) | 3.43 (2.66 to 4.43) | 2.71 (2.08 to 3.52) |
| Time since sarcoidosis diagnosis, years | | | |
| ≤2 | 4.69 (3.70 to 5.95) | 4.73 (3.73 to 6.00) | 3.74 (2.93 to 4.77) |
| >2 | 2.30 (1.87 to 2.84) | 2.32 (1.88 to 2.86) | 1.86 (1.50 to 2.31) |
| History of ischaemic heart disease or acute myocardial infarction | | | |
| Yes | 2.05 (1.44 to 2.92) | 2.06 (1.45 to 2.94) | 1.70 (1.19 to 2.44) |
| No | 3.32 (2.79 to 3.96) | 3.35 (2.82 to 3.99) | 2.74 (2.28 to 3.29) |

*HRs were estimated using Cox proportional hazards models with attained age as the time scale. The multivariable model 1 was adjusted for age at start of follow-up, sex and region of residence. The multivariable model 2 was further adjusted for country of birth, education, civil status and calendar period. The multivariable model 3 was further adjusted for healthcare visits within 2 years before inclusion, history of hypertension, diabetes mellitus, dyslipidaemia, heart valve disease, atrial fibrillation, chronic obstructive pulmonary disease, chronic kidney disease, alcohol-related disorders and autoimmune disease. Differences in HRs from the multivariable model 3 among groups were tested using likelihood ratio tests: age at start of follow-up (p=0.77); sex (p=0.38); sarcoidosis treatment around diagnosis (p=0.29); time since sarcoidosis diagnosis (p<0.001); history of ischaemic heart disease or acute myocardial infarction (p=0.02).†Evaluated in individuals with start of follow-up from 2006 and onwards for whom medication dispensation data were available in the Prescribed Drug Register.
however, that a higher risk of death in the treated compared with the untreated may have led to a slight underestimation of the true HR of HF in the first. In a separate analysis among treated patients with sarcoidosis, we found that a higher dose of systemic corticosteroids dispensed within 6 months after sarcoidosis diagnosis was associated with a higher hazard of HF thereafter. The role of immunosuppressant treatment, especially that of corticosteroids, should be investigated further with larger numbers while accounting for disease severity that is an indication for treatment.

### Table 4  HRs of heart failure in sarcoidosis associated with covariates evaluated at start of follow-up (second visit for sarcoidosis in the National Patient Register)

| Heart failure | HR* (95% CI) |
|---------------|-------------|
| Age at sarcoidosis diagnosis, years | | |
| Yes (n=204) | No (n=8370) | Univariable | Multivariable model 1 | Multivariable model 2 |
| 67 (59, 76) | 48 (37, 60) | 2.4 (2.2 to 2.7) | — | 1.9 (1.7 to 2.2) |
| Male | | 1.0 (0.8 to 1.3) | — | 1.5 (1.1 to 2.0) |
| Education, years | | |
| ≤9 | 98 (48) | 1781 (21) | 4.1 (2.8 to 6.1) | — | 1.9 (1.3 to 2.9) |
| 10–12 | 73 (36) | 4129 (49) | 1.3 (0.9 to 2.0) | — | 1.3 (0.9 to 2.0) |
| ≥13 | 33 (16) | 2460 (29) | 1.0 (reference) | — | 1.0 (reference) |
| Hypertension | | |
| Yes (n=204) | No (n=8370) | Univariable | Multivariable model 1 | Multivariable model 2 |
| 107 (52) | 1789 (21) | 5.7 (4.3 to 7.5) | 2.2 (1.6 to 2.9) | 1.2 (0.9 to 1.7) |
| Diabetes mellitus | | |
| Yes (n=204) | No (n=8370) | Univariable | Multivariable model 1 | Multivariable model 2 |
| 58 (28) | 609 (7) | 6.2 (4.5 to 8.4) | 3.2 (2.3 to 4.4) | 2.5 (1.8 to 3.6) |
| Chronic kidney disease | | |
| Yes (n=204) | No (n=8370) | Univariable | Multivariable model 1 | Multivariable model 2 |
| 20 (10) | 173 (2) | 6.2 (3.9 to 9.9) | 1.9 (1.2 to 3.1) | 1.4 (0.8 to 2.2) |
| Alcohol-related disease | | |
| Yes (n=204) | No (n=8370) | Univariable | Multivariable model 1 | Multivariable model 2 |
| 10 (5) | 186 (2) | 2.9 (1.5 to 5.5) | 2.4 (1.3 to 4.5) | 2.0 (1.0 to 3.9) |
| Chronic obstructive pulmonary disease | | |
| Yes (n=204) | No (n=8370) | Univariable | Multivariable model 1 | Multivariable model 2 |
| 11 (5) | 225 (3) | 2.4 (1.3 to 4.4) | 1.1 (0.6 to 2.1) | 1.1 (0.6 to 2.1) |
| Heart valve disease | | |
| Yes (n=204) | No (n=8370) | Univariable | Multivariable model 1 | Multivariable model 2 |
| 16 (8) | 73 (1) | 11.1 (6.6 to 18.5) | 3.8 (2.2 to 6.4) | 1.8 (1.0 to 3.1) |
| Ischaemic heart disease or acute myocardial infarction | | |
| Yes (n=204) | No (n=8370) | Univariable | Multivariable model 1 | Multivariable model 2 |
| 47 (23) | 343 (4) | 7.7 (5.6 to 10.7) | 2.4 (1.7 to 3.4) | 1.4 (1.0 to 2.1) |
| Atrial fibrillation | | |
| Yes (n=204) | No (n=8370) | Univariable | Multivariable model 1 | Multivariable model 2 |
| 49 (24) | 214 (3) | 13.6 (9.9 to 18.8) | 4.6 (3.2 to 6.5) | 2.6 (1.8 to 3.9) |
| Other arrhythmia or heart block | | |
| Yes (n=204) | No (n=8370) | Univariable | Multivariable model 1 | Multivariable model 2 |
| 39 (19) | 277 (3) | 8.1 (5.7 to 11.5) | 4.2 (2.9 to 6.0) | 2.5 (1.6 to 3.7) |
| Pulmonary hypertension | | |
| Yes (n=204) | No (n=8370) | Univariable | Multivariable model 1 | Multivariable model 2 |
| ≤5 (2) | 7 (<1) | Not estimable | Not estimable | Not estimable |
| Autoimmune disease | | |
| Yes (n=204) | No (n=8370) | Univariable | Multivariable model 1 | Multivariable model 2 |
| 27 (13) | 674 (8) | 2.0 (1.3 to 3.0) | 1.7 (1.1 to 2.5) | 1.1 (0.7 to 1.7) |

Data are n (%) or median (IQR).

*HRs were estimated from Cox proportional hazards models with years since sarcoidosis diagnosis as the time scale. The multivariable model 1 included age (continuous), sex, region of residence (six healthcare regions), country of birth (Nordic/non-Nordic) and education. The multivariable model 2 included the covariates age, sex, region of residence, country of birth, education and all comorbidities in the table except pulmonary hypertension due to small numbers.

†Effect per 10-year increase.

‡Category ‘≤9 years’ includes <1% missing.

Figure 1  Fraction of heart failure cases at 2 and 10 years after sarcoidosis diagnosis attributed to risk factors evaluated at start of follow-up (second visit for sarcoidosis in the National Patient Register). Attributable fractions were estimated using a Cox model with years since sarcoidosis diagnosis as the time scale and the following time-fixed covariates: age (continuous), sex, region of residence (six healthcare regions), country of birth (Nordic/non-Nordic), education (in three categories) and comorbidities listed in the figure. Error bars indicate 95% CIs.
Among patients with sarcoidosis, sociodemographic factors such as older age, male sex and lower education were associated with a higher hazard of HF. Diabetes mellitus and atrial fibrillation, two traditional risk factors of HF, were among the strongest predictors of HF diagnosis also in sarcoidosis. However, no association was observed between hypertension and HF likely due to the inclusion of other predictors of cardiovascular disease. Risks of diabetes and atrial fibrillation peak immediately after sarcoidosis diagnosis and although it is disputed whether the latter is a manifestation of cardiac sarcoidosis, their presence might lead to diagnosis of HF. A large proportion of future HF cases (≥35%) could therefore be attributed to factors unrelated to sarcoid heart involvement.

In our study, 19% of patients with sarcoidosis who developed HF had a diagnosis of a ventricular arrhythmia, heart block or cardiac arrest; their prevalence increased to 30% during follow-up. Presumed to be a consequence of cardiac sarcoidosis, a composite predictor including these severe arrhythmias was independently and equally predictive of increased HF in sarcoidosis as other traditional HF risk factors. Although one study showed congestive HF was more common in patients hospitalised for sarcoidosis with than those without an arrhythmia, data on HF risk factors from other populations are scarce to compare our findings.

IHD and AMI, strong predictors of HF in the general population and other inflammatory diseases, were less predictive of HF in sarcoidosis accounting for 7% of HF cases 2 years after sarcoidosis diagnosis. Even though HF rates in our study were notably higher in those with IHD compared with those without irrespective of sarcoidosis status, a higher HR of HF associated with sarcoidosis was observed in those without a history of IHD (2.7 vs 1.7). This observation supports the notion that cardiac sarcoidosis and not IHD alone drives the increased HR of HF. Indeed, unpublished findings showing similar risks of AMI between sarcoidosis and the general population are suggestive of a weaker role of IHD on HF in sarcoidosis.

Certain limitations of this study are worth considering. No data are available in the NPR to characterise the precise aetiology or severity of HF or define cardiac sarcoidosis. Moreover, because sarcoidosis and HF share symptoms and the diagnostic work-up for the first may reveal the latter, differential misclassification of HF was possible. However, our findings are unlikely to have been greatly affected by this bias as shown in a sensitivity analysis where we disregarded HF diagnoses during the first 6 months since sarcoidosis diagnosis, which yielded similar results to the main analysis. In addition, HF rates reported here may be somewhat underestimated as we have missed some HF cases treated solely in primary care data from which we did not have.

Furthermore, we lacked data on obesity and smoking, two potential confounders of the association between sarcoidosis and HF. It is unlikely, however, that knowledge of these factors would have altered our conclusions by explaining away the strong association. That is because the magnitude of the positive association between obesity and sarcoidosis is the same to that of the inverse association between smoking and sarcoidosis. Assuming also a similar effect on HF risk and in the absence of substantial interactions, we would expect a null net effect on the sarcoidosis–HF associations. Our findings are transportable to populations with similar prevalence and severity of cardiac sarcoidosis and other comorbidities predisposing to HF.

Overall, individuals with sarcoidosis are at a considerably higher risk of developing HF compared with the general population, especially during the first 2 years after sarcoidosis diagnosis. Traditional risk factors such as older age, diabetes mellitus and IHD are associated with an increased hazard of HF in sarcoidosis but are unlikely to explain all the observed risks in this population. Ventricular and other arrhythmias, which may be related to cardiac sarcoidosis, are one of the strongest independent predictors of HF and may be responsible for more than 10% of HF cases within 2 years after sarcoidosis diagnosis. Further studies are warranted to identify optimal measures that could help prevent HF in high-risk individuals with sarcoidosis.
been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID ID
Marios Rossides http://orcid.org/0000-0002-9769-324X

REFERENCES

1. Bloom MW, Greenberg B, Jaarsma T, et al. Heart failure with reduced ejection fraction. *Nat Rev Dis Primers* 2017;3:17058.

2. Rossides M, Kullberg S, Askling J, et al. Sarcoidosis mortality in Sweden: a population-based cohort study. *Eur Respir J* 2018;51:1701815.

3. Ungprasert P, Crowson CS, Matteson EL. Risk of cardiovascular disease among patients with sarcoidosis: a population-based retrospective cohort study, 1976-2013. *Eur Respir J* 2017;49:1601290.

4. Yafasova A, Fosbol EL, Schou M, et al. Long-term adverse cardiac outcomes in patients with sarcoidosis. *J Am Coll Cardiol* 2020;76:767–77.

5. Ethinger R, Comaneshter D, Amital H, et al. Cardiac involvement in sarcoidosis: evolving concepts in diagnosis and treatment. *Semin Respir Crit Care Med* 2020;41:626–40.

6. Birnie DH. Cardiac sarcoidosis. *Semin Respir Crit Care Med* 2017;38:477–98.

7. Te ALD, Lin Y-J, Chen Y-Y, et al. Increased risk of ventricular tachycardia in patients with sarcoidosis during the very long term follow-up. *Int J Cardiol* 2017;228:68–73.

8. Sayah DM, Bradfield JS, Moriarty JM, et al. Cardiac involvement in sarcoidosis: a population-based inpatient analysis. *Ann Transl Med* 2018;6:330.

9. Cacoub P, Chapelon-Abic C, Resche-Rigon M, et al. Cardiac sarcoidosis: a long term follow up study. *PloS One* 2020;15:e0238391.

10. Weng W, Wiefer G, Chakrabarti S, et al. Atrial arrhythmias in clinically manifest cardiac sarcoidosis: incidence, burden, predictors, and outcomes. *J Am Heart Assoc* 2020;9:e017086.